CompletedNCT01862640
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
Medication studyAges 55–90Multiple countriesMental health
Understand this study
Who was this study for?
Listed age limits: 55 years to 90 years.
- Listed locations
- Tuscaloosa and 84 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: July 11, 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 433
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Croatia, Germany, ...
- Age range
- From 55 Years to 90 Years
- Official registry ID
- NCT01862640
- Official title
Show the full official title
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedTuscaloosa, United States · Phoenix, United States · Bellflower, United States
64 more locations
- Costa Mesa, United States
- Downey, United States
- Orange, United States
- Redlands, United States
- Yorba Linda, United States
- Norwalk, United States
- Coconut Creek, United States
- Hialeah, United States
- Lauderhill, United States
- Miami, United States
- Miami Springs, United States
- Sarasota, United States
- Decatur, United States
- Suwanee, United States
- Weymouth, United States
- St Louis, United States
- Las Vegas, United States
- Mount Arlington, United States
- Paterson, United States
- Toms River, United States
- Hickory, United States
- Oklahoma City, United States
- Franklin, United States
- Bedford, United States
- Waukesha, United States
- Rijeka, Croatia
- Zadar, Croatia
- Zagreb, Croatia
- Mittweida, Germany
- Achim, Germany
- Berlin, Germany
- Bielefeld, Germany
- Bochum, Germany
- Cologne, Germany
- Hamburg, Germany
- Ostfildern, Germany
- Westerstede, Germany
- Saint Petersburg, Russia
- Samara, Russia
- Saratov, Russia
- Tonnel'nyy, Russia
- Yekaterinburg, Russia
- Belgrade, Serbia
- Kovin, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Novi Kneževac, Serbia
- Novi Sad, Serbia
- Vršac, Serbia
- Barcelona, Spain
- Getafe, Spain
- Girona, Spain
- Madrid, Spain
- Pamplona, Spain
- Salamanca, Spain
- Valencia, Spain
- Zamora, Spain
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kiev, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Brexpiprazole, OPC-34712 and Placebo Oral Tablet.
Who was this study for?
Listed age limits: 55 years to 90 years.
